Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension

Blood

Volumn 119, Issue 7, 2012, Pages 1772-1780

  Launay, Jean Marie ^a   Hervé, Philippe ^b   Callebert, Jacques ^a   Mallat, Ziad ^c   Collet, Corinne ^a   Doly, Stéphane ^d   Belmer, Arnauld ^d   Diaz, Silvina L ^d   Hatia, Sarah ^e   Côté, Francine ^e   Humbert, Marc ^f   Maroteaux, Luc ^d  

^a INSERM   (France)

^b CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d INSTITUT DU FER À MOULIN   (France)

^e CNRS   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; MONOCROTALINE; SEROTONIN 2 ANTAGONIST; SEROTONIN 2B RECEPTOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; FEMALE; HEMATOLOGICAL PARAMETERS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HYPOXIA; MONOCYTE MACROPHAGE PRECURSOR CELL; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; STEM CELL MOBILIZATION; THROMBOCYTE; VASCULAR REMODELING; ANIMAL; BIOLOGICAL MODEL; BLOOD; BLOOD ANALYSIS; BONE MARROW; BONE MARROW CELL; CELL CULTURE; GENETICS; IMMUNOLOGY; LUNG; MALE; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; BLOOD; BLOOD CHEMICAL ANALYSIS; BONE MARROW; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, SEROTONIN, 5-HT2B;

EID: 84857499429     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-358374     Document Type: Article

References (47)

1. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation. 2010;121(18):2045-2066.
2. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res. 2006;99(7):675-691.
3. Wang CH, Anderson N, Li SH, et al. Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate. Circ Res. 2006;99(6):617-625.
4. Asosingh K, Aldred MA, Vasanji A, et al. Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am J Pathol. 2008;172(3):615-627.
5. Marsboom G, Pokreisz P, Gheysens O, et al. Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension. Stem Cells. 2008;26(4):1017-1026.
6. Frid MG, Brunetti JA, Burke DL, et al. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol. 2006;168(2):659-669.
7. Hayashida K, Fujita J, Miyake Y, et al. Bone marrow-derived cells contribute to pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension. Chest. 2005;127(5):1793-1798.
8. Davie NJ, Crossno JT, Frid MG, et al. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol. 2004;286(4):L668-678.
9. Diller G-P, Thum T, Wilkins MR, Wharton J. Endothelial progenitor cells in pulmonary arterial hypertension. Trends Cardiovasc Med. 2010;20(1):22-29.
10. Yoder M, Rounds S. Bad blood, bad endothelium: ill fate? Blood. 2011;117(13):3479-3480.
11. Limsuwan A, Pakakasama S, Rochanawutanon M, Hong-Eng S. Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology. 2006;105(3):188-194.
12. Farha S, Asosingh K, Xu W, et al. Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood. 2011;117(13):3485-3493.
13. Steward CG, Pellier I, Mahajan A, et al. Severe pulmonary hypertension: a frequent complication of stem cell transplantation for malignant infantile osteopetrosis. Br J Haematol. 2004;124(1):63-71.
14. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol. 2008;44(1):14-30.
15. Weir EK, Obreztchikova M, Hong Z. Fenfluramine: riddle or Rosetta stone? Eur Respir J. 2008;31(2):232-235.
16. Launay JM, Hervé P, Peoc'h K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med. 2002;8(10):1129-1135.
17. Dumitrascu R, Kulcke C, Königshoff M, et al. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J. 2011; 37(5):1104-1118.
18. Zopf DA, das Neves LA, Nikula KJ, Huang J, Senese PB, Gralinski MR. C-122, a novel antagonist of serotonin receptor 5-HT(2B), prevents monocrotaline-induced pulmonary arterial hypertension in rats. Eur J Pharmacol. 2011;670(1):195-203.
19. Porvasnik SL, Germain S, Embury J, et al. PRX- 08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. J Pharmacol Exp Ther. 2010;334(2):364-372.
20. Yang M, Li K, Ng PC, et al. Promoting effects of serotonin on hematopoiesis: ex vivo expansion of cord blood CD34+ stem/progenitor cells, proliferation of bone marrow stromal cells, and antiapoptosis. Stem Cells. 2007;25(7):1800-1806.
21. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351(16):1655-1665.
22. Nebigil CG, Choi D-S, Dierich A, et al. Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci U S A. 2000;97:9508-9513.
23. Potteaux S, Combadiere C, Esposito B, et al. Role of bone marrow-derived CC-chemokine receptor 5 in the development of atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2006;26(8):1858-1863.
24. Spees JL, Whitney MJ, Sullivan DE, et al. Bone marrow progenitor cells contribute to repair and remodeling of the lung and heart in a rat model of progressive pulmonary hypertension. FASEB J. 2008;22(4):1226-1236.
25. Schneider E, Machavoine F, Pleau JM, et al. Organic cation transporter 3 modulates murine basophil functions by controlling intracellular histamine levels. J Exp Med. 2005;202(3):387-393.
26. Gambaryan N, Perros F, Montani D, et al. Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. Eur Respir J. 2011;37(6):1392-1399.
27. Montani D, Perros F, Gambaryan N, et al. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011;184(1):116-123.
28. Amireault P, Hatia S, Bayard E, et al. Ineffective erythropoiesis with reduced red blood cell survival in serotonin-deficient mice. Proc Natl Acad Sci U S A. 2011;108(32):13141-13146.
29. Hercus TR, Thomas D, Guthridge MA, et al. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood. 2009;114(7):1289-1298.
30. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182(9):1171-1177.
31. Sata M. Role of circulating vascular progenitors in angiogenesis, vascular healing, and pulmonary hypertension: lessons from animal models. Arterioscler Thromb Vasc Biol. 2006;26(5):1008-1014.
32. Fazel SS, Chen L, Angoulvant D, et al. Activation of c-kit is necessary for mobilization of reparative bone marrow progenitor cells in response to cardiac injury. FASEB J. 2008;22(3):930-940.
33. Gambaryan N, Perros F, Montani D, Cohen-Kaminsky S, Mazmanian GM, Humbert M. Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension. Eur Respir J. 2010;36(5):1209-1211.
34. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295(1):139-145.
35. Huang XP, Setola V, Yadav PN, et al. Parallel functional activity profiling reveals valvulopathogens are potent 5-HT2B receptor agonists: implications for drug safety assessment. Mol Pharmacol. 2009;76(4):710-722.
36. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115(10):2811- 2821.
37. Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995;99(3):249-254.
38. Morecroft I, Dempsie Y, Bader M, et al. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension. 2007;49(1):232-236.
39. Pirson L, Baron F, Meuris N, et al. Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice. Stem Cells. 2006;24(7):1814-1821.
40. Liu YS, Yang M. The effect of 5-hydroxtryptamine on the regulation of megakaryocytopoiesis. Hematology. 2006;11(1):53-56.
41. Battinelli E, Loscalzo J. Nitric oxide induces apoptosis in megakaryocytic cell lines. Blood. 2000;95(11):3451-3459.
42. Nebigil CG, Etienne N, Messaddeq N, Maroteaux L. Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-HT2B-receptor signaling. FASEB J. 2003;17(10):1373-1375.
43. Popat U, Frost A, Liu E, et al. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood. 2006;107(9):3486-3488.
44. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964-967.
45. Shimizu K, Sugiyama S, Aikawa M, et al. Host BM cells are a source of donor intimal smoothmuscle- like cells in murine aortic transplant arteriopathy. Nat Med. 2001;7(6):738-741.
46. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002;8(4):403-409.
47. Bailey AS, Willenbring H, Jiang S, et al. Myeloid lineage progenitors give rise to vascular endothelium. Proc Natl Acad Sci U S A. 2006;103(35):13156-13161.